The newest data on Pfizer's
The drug reduced the risk of both spinal and non-spinal fractures, but it doesn't appear to work any better than Eli Lilly's
Pfizer has said that it would like to sell or license Fablyn, which it originally licensed from Ligand Pharmaceuticals. But who's going to buy it? A large sales force would probably be necessary, since osteoporosis is often treated by a primary-care physician and not a specialist. That cuts out most specialty pharmaceutical companies. Even Amgen
Companies |
Drug |
---|---|
Eli Lilly |
Evista |
Procter & Gamble |
Actonel |
Novartis |
Reclast |
Roche and GlaxoSmithKline |
Boniva |
Who knows? Maybe one of those companies will see a niche market for Fablyn that might not cannibalize their current offering. There's also Merck
Given the crowded market and the lack of clinical advantages that Fablyn has demonstrated, I wouldn't expect Pfizer to be able to get much for the compound.
Bone up on this trend that may change investing.